Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle

Core Insights - Pfizer Inc. generated over $85 billion from its COVID vaccine Comirnaty and over $20 billion from its antiviral Paxlovid between 2021 and 2023 [2] Group 1: Company Performance - Pfizer's COVID vaccine Comirnaty earned the company more than $85 billion from 2021 to 2023 [2] - The COVID antiviral Paxlovid contributed over $20 billion in revenue during the same period [2] Group 2: Analyst and Market Insights - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including product sales forecasts and market analysis for major pharmaceutical companies [2]